期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 11, 期 6, 页码 645-653出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0084
关键词
-
类别
资金
- Exelixis Inc.
- Abraxis Oncology
- Boehringer Ingelheim GmbH
- Celgene Corporation
- Genentech, Inc.
- GlaxoSmithKline
- Pfizer Inc
- Pharmacyclics
- Eli Lilly and Company
- Eisai, Inc.
- Millennium
- Takeda Oncology Company
- Teva Pharmaceuticals
- Bayer HealthCare Pharmaceuticals Inc.
- Endo Pharmaceuticals and HealthTronics
- Genentech
- ARIAD Pharmaceuticals, Inc.
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据